Umami Bioworks
PrivateLast Round
Seed
Aug 30, 2023
Total Funding Raised
$2.4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Umami Bioworks operates in Healthcare & Life Sciences and is based in Singapore. Its latest recorded funding round was a Seed round in August 2023.
Umami Bioworks is a food technology company that develops cultivated seafood using stem cell biology, machine learning, and automation to provide a sustainable alternative to traditional seafood.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Sustainable Materials, Clean Manufacturing
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Umami Bioworks Comparables
Compare Umami Bioworks with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| EFISHient Protein | 84% | |
| Avant Meats | 83% | |
| Cell4Food | 82% |
For institutional investors. Book with your work email.
Umami Bioworks Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Aug 30, 2023 | ||||
| Grant | Jan 3, 2023 | ||||
| Grant | Nov 17, 2022 | ||||
| Pre Seed | Mar 2, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Umami Bioworks Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CULT Food Science | Pre Seed |
| SVG Ventures|THRIVE | Grant |
| Singapore-Israel Industrial R&D Foundation | Grant |
| Plug and Play Tech Center | Pre Seed, Grant |
| The Yield Lab Asia Pacific | Pre Seed |
| Better Bite Ventures | Pre Seed |
| Better Bite Ventures | Pre Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 84% MoM, from 9.8K to 18K.
- Nov 26, 2025
Launched Virtual Marine Cell, an AI-powered metabolic simulator for aquatic species.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 5, 2026
Umami Bioworks Pte Ltd. partnered with IntegriCulture in 2025 to develop novel cosmetics using Cellament and its own cultured fish cells.
For institutional investors. Book with your work email.
Umami Bioworks Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Umami Bioworks's valuation, stock price, and market status.
Is Umami Bioworks a public or private company?
Umami Bioworks is a private company.
What is the current stock price of Umami Bioworks?
Umami Bioworks is a private company, so its shares have no public market price. Caplight tracks Umami Bioworks's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Umami Bioworks worth (valuation)?
Valuation information for Umami Bioworks is not publicly available.
Can I buy Umami Bioworks stock?
Umami Bioworks shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Umami Bioworks's last funding round?
Umami Bioworks's most recent funding round was Seed on August 30, 2023.
Who are the main investors in Umami Bioworks?
Key investors in Umami Bioworks include SVG Ventures|THRIVE, Better Bite Ventures, Better Bite Ventures, Genedant.
Will Umami Bioworks IPO soon?
No public IPO plans have been announced for Umami Bioworks.
How can I track Umami Bioworks secondary market activity?
Caplight tracks bids, offers, and trades in Umami Bioworks's shares on secondary markets.